Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth

Natale D'Alessandro, Giuseppe Montalto, Monica Notarbartolo Di Villarosa, Lydia Giannitrapani, Antonella Cusimano, Nadia Lampiasi, Daniela Foderà, Melchiorre Cervello, Antonina Azzolina

Risultato della ricerca: Article

19 Citazioni (Scopus)

Abstract

The aim of this study was to investigate the expression of prostaglandin E(2) receptors (EP(1-4)), cyclooxygenase-1 (COX-1), and COX-2 in nontumor and tumor human liver tissues, and also to evaluate the antitumor activity of selective EP(1) receptor antagonist used alone or in combination with COX-1 and COX-2 selective inhibitors. Semiquantitative PCR analyses revealed that EP(1-4), COX-1, and COX-2 mRNA expression Was detected in nearly all the tissue samples assayed, although with a high variability between nontumor and tumor tissues. In vitro EP(1) receptor antagonist inhibited anchorage-independent cell growth and reduced the viability of hepatocellular carcinoma (HCC) cells in a dose-dependent manner. Moreover, treatment with the combination of EP(1) receptor antagonist and COX inhibitors produced a significantly greater cell growth inhibition than the single agent alone. These findings suggest that the EP(1) receptor may represent an important target for HCC treatment, and in addition they could provide preclinical support for a combined chemotherapeutic approach with EP(1) antagonists and COX inhibitors in the treatment of liver cancer
Lingua originaleEnglish
pagine (da-a)300-308
Numero di pagine9
RivistaAnnals of the New York Academy of Sciences
Volume1155
Stato di pubblicazionePublished - 2009

Fingerprint

Prostaglandin Receptors
Cyclooxygenase 1
Cell growth
Dinoprostone
Hepatocellular Carcinoma
Tissue
Liver
Tumors
Receptors, Prostaglandin E, EP2 Subtype
Enzymes
Growth
Cyclooxygenase 2 Inhibitors
Liver Neoplasms
Neoplasms
Cells
Polymerase Chain Reaction
Messenger RNA
Antagonist

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • History and Philosophy of Science
  • Biochemistry, Genetics and Molecular Biology(all)

Cita questo

Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. / D'Alessandro, Natale; Montalto, Giuseppe; Notarbartolo Di Villarosa, Monica; Giannitrapani, Lydia; Cusimano, Antonella; Lampiasi, Nadia; Foderà, Daniela; Cervello, Melchiorre; Azzolina, Antonina.

In: Annals of the New York Academy of Sciences, Vol. 1155, 2009, pag. 300-308.

Risultato della ricerca: Article

@article{4787200975644424a12afa2371ec9a00,
title = "Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth",
abstract = "The aim of this study was to investigate the expression of prostaglandin E(2) receptors (EP(1-4)), cyclooxygenase-1 (COX-1), and COX-2 in nontumor and tumor human liver tissues, and also to evaluate the antitumor activity of selective EP(1) receptor antagonist used alone or in combination with COX-1 and COX-2 selective inhibitors. Semiquantitative PCR analyses revealed that EP(1-4), COX-1, and COX-2 mRNA expression Was detected in nearly all the tissue samples assayed, although with a high variability between nontumor and tumor tissues. In vitro EP(1) receptor antagonist inhibited anchorage-independent cell growth and reduced the viability of hepatocellular carcinoma (HCC) cells in a dose-dependent manner. Moreover, treatment with the combination of EP(1) receptor antagonist and COX inhibitors produced a significantly greater cell growth inhibition than the single agent alone. These findings suggest that the EP(1) receptor may represent an important target for HCC treatment, and in addition they could provide preclinical support for a combined chemotherapeutic approach with EP(1) antagonists and COX inhibitors in the treatment of liver cancer",
author = "Natale D'Alessandro and Giuseppe Montalto and {Notarbartolo Di Villarosa}, Monica and Lydia Giannitrapani and Antonella Cusimano and Nadia Lampiasi and Daniela Foder{\`a} and Melchiorre Cervello and Antonina Azzolina",
year = "2009",
language = "English",
volume = "1155",
pages = "300--308",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth

AU - D'Alessandro, Natale

AU - Montalto, Giuseppe

AU - Notarbartolo Di Villarosa, Monica

AU - Giannitrapani, Lydia

AU - Cusimano, Antonella

AU - Lampiasi, Nadia

AU - Foderà, Daniela

AU - Cervello, Melchiorre

AU - Azzolina, Antonina

PY - 2009

Y1 - 2009

N2 - The aim of this study was to investigate the expression of prostaglandin E(2) receptors (EP(1-4)), cyclooxygenase-1 (COX-1), and COX-2 in nontumor and tumor human liver tissues, and also to evaluate the antitumor activity of selective EP(1) receptor antagonist used alone or in combination with COX-1 and COX-2 selective inhibitors. Semiquantitative PCR analyses revealed that EP(1-4), COX-1, and COX-2 mRNA expression Was detected in nearly all the tissue samples assayed, although with a high variability between nontumor and tumor tissues. In vitro EP(1) receptor antagonist inhibited anchorage-independent cell growth and reduced the viability of hepatocellular carcinoma (HCC) cells in a dose-dependent manner. Moreover, treatment with the combination of EP(1) receptor antagonist and COX inhibitors produced a significantly greater cell growth inhibition than the single agent alone. These findings suggest that the EP(1) receptor may represent an important target for HCC treatment, and in addition they could provide preclinical support for a combined chemotherapeutic approach with EP(1) antagonists and COX inhibitors in the treatment of liver cancer

AB - The aim of this study was to investigate the expression of prostaglandin E(2) receptors (EP(1-4)), cyclooxygenase-1 (COX-1), and COX-2 in nontumor and tumor human liver tissues, and also to evaluate the antitumor activity of selective EP(1) receptor antagonist used alone or in combination with COX-1 and COX-2 selective inhibitors. Semiquantitative PCR analyses revealed that EP(1-4), COX-1, and COX-2 mRNA expression Was detected in nearly all the tissue samples assayed, although with a high variability between nontumor and tumor tissues. In vitro EP(1) receptor antagonist inhibited anchorage-independent cell growth and reduced the viability of hepatocellular carcinoma (HCC) cells in a dose-dependent manner. Moreover, treatment with the combination of EP(1) receptor antagonist and COX inhibitors produced a significantly greater cell growth inhibition than the single agent alone. These findings suggest that the EP(1) receptor may represent an important target for HCC treatment, and in addition they could provide preclinical support for a combined chemotherapeutic approach with EP(1) antagonists and COX inhibitors in the treatment of liver cancer

UR - http://hdl.handle.net/10447/45659

M3 - Article

VL - 1155

SP - 300

EP - 308

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -